ZAI LAB (09688) total revenue for the year 2024 is $399 million, a year-on-year increase of 50%.

ZAI LAB (09688) announced its annual performance as of December 31, 2024, with total revenue of 399 million US dollars, a year-on-year increase of 50%; the annual revenue guidance for 2025 is between 560 million US dollars and 590 million US dollars. The sales revenue of Wei Wei Jia and Wei Li Jia in the fourth quarter of 2024 reached 30 million US dollars, and the annual sales revenue for 2024 reached 93.6 million US dollars. Early clinical data for a Phase 1 study for small cell lung cancer (SCLC) showed an ORR of 74%, ZL-1310 (DLL3 ADC) has the potential to be a first-in-class and best-in-class drug of its kind; ZAI LAB has global rights to ZL-1310 and is expected to announce updated research data for SCLC at a major medical conference in the first half of 2025, as well as explore the potential for other neuroendocrine tumors in the first half of 2025. Key regional pipelines continue to advance, including the acceptance of the New Drug Application (NDA) for KarXT for the treatment of schizophrenia, further strengthening ZAI LAB's immune pipeline with late-stage assets including povetacicept for IgAN. Dr. Samantha Du, founder, chairman, and CEO of ZAI LAB, said, "2024 was a decisive year for ZAI LAB, with strong sales growth, solid financials, and significant pipeline progress. Looking ahead, with the continued growth of Egamode, the launch of three new products, the progress of ZL-1310, and potential registration milestones for key pipeline assets, 2025 will be a transformative year for us. Egamode achieved net product revenues of $93.6 million in its first complete year of listing, highlighting the urgent need for innovative therapies among Chinese patients. In January of this year, the National Medical Products Administration (NMPA) accepted the NDA for KarXT, taking us one step closer to bringing this innovative drug to Chinese patients in need. Meanwhile, the pipeline ZL-1310, for which we hold global rights, has shown outstanding safety and efficacy data, demonstrating its potential to be a first-in-class and best-in-class DLL3 antibody-drug conjugate (ADC) for treating SCLC. Today's ZAI LAB is stronger than ever, with the solid foundation, innovation, and execution needed to bring drugs to global patients and create value for our shareholders."